Sections
| Title | Starting Page | Number of Pages |
|---|
| COVER | 1 | 2 |
| PLUNKETT S BIOTECH &GENETICS INDUSTRY TRENDS &STATISTICS 2015 | 3 | 3 |
| CONTENTS | 6 | 2 |
| Chapter 1 MAJOR TRENDS AFFECTING THE BIOTECH &GENETICS INDUSTRY | 8 | 34 |
| 1) The State of the Biotechnology Industry Today | 9 | 3 |
| 2) A Short History of Biotechnology | 12 | 1 |
| 3) Ethanol Production Soared, But U.S. Federal Subsidy Expires | 13 | 2 |
| 4) Major Drug Companies Acquire or Partner with Smaller Biotech Firms | 15 | 1 |
| 5) U.S. Drug Manufacturers Seek Tax Breaks by Acquiring Overseas Firms | 16 | 1 |
| 6) From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development | 16 | 2 |
| 7) Patients Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance | 18 | 1 |
| 8) Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing | 19 | 1 |
| 9) Vaccines and Viruses in Drug Delivery | 20 | 1 |
| 10) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues/Drug Prices Soar | 21 | 3 |
| 11) Biotech and Orphan Drugs Create New Revenues for Drug Firms | 24 | 1 |
| 12) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce | 25 | 2 |
| 13) Drug Delivery Systems Evolve to Meet the Needs of Biotech Drugs | 27 | 1 |
| 14) Stem Cells Multiple Sources Stem from New Technologies | 27 | 2 |
| 15) Government Support for New Stem Cell Research Evolves | 29 | 1 |
| 16) Stem Cells Therapeutic Cloning Techniques Advance | 30 | 1 |
| 17) Stem Cells A New Era of Tissue Replacement Takes Shape | 31 | 2 |
| 18) Nanotechnology Converges with Biotech | 33 | 1 |
| 19) Genetically Modified Seeds and Crops (GMOs) | 34 | 1 |
| 20) Genetically Modified (GM) Foods | 35 | 1 |
| 21) Molecular Farming of Plant-Based Pharmaceuticals | 35 | 1 |
| 22) Cloning of Farm Animals/Meat Grown in the Laboratory | 36 | 1 |
| 23) Selective Breeding, Zinc Fingers and Mutagenesis as Alternatives to GMOs | 36 | 1 |
| 24) Immunotherapy Promises New Approach to Fighting Cancers | 37 | 1 |
| 25) Technology Discussion Genes and DNA | 37 | 1 |
| 26) Technology Discussion Proteins and Proteomics | 38 | 1 |
| 27) Technology Discussion Microarrays | 38 | 1 |
| 28) Technology Discussion DNA Chips | 38 | 1 |
| 29) Technology Discussion SNPs ( Snips ) | 39 | 1 |
| 30) Technology Discussion Combinatorial Chemistry | 39 | 1 |
| 31) Technology Discussion Synthetic Biology | 39 | 1 |
| 32) Technology Discussion Recombinant DNA | 40 | 1 |
| 33) Technology Discussion Polymerase Chain Reaction (PCR) | 40 | 2 |
| Chapter 2 BIOTECH &GENETICS INDUSTRY STATISTICS | 42 | 19 |
| Biotech Industry Overview | 43 | 1 |
| The U.S. Drug Discovery &Approval Process | 44 | 1 |
| U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2013 | 45 | 1 |
| U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2013 | 46 | 1 |
| Employment in Life &Physical Science Occupations by Business Type, U.S.: May 2013 | 47 | 1 |
| Federal R&D &R&D Plant Funding for General Science &Basic Research, U.S.: Fiscal Years 2012-2014 | 48 | 1 |
| U.S. Exports &Imports of Pharmaceutical Products: 2008-1st Quarter 2014 | 49 | 1 |
| U.S. Prescription Drug Expenditures, Aggregate &Per Capita Amounts, Percent Distribution: 2006-2022 | 50 | 2 |
| Prescription Drug Expenditures, U.S.: Selected Years, 1960-2022 | 52 | 1 |
| Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2013 | 53 | 1 |
| Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2013-2015 | 54 | 1 |
| Global Area of Biotech Crops by Country: 2013 | 55 | 1 |
| Domestic &Foreign Pharmaceutical Sales, PhRMA Member Companies: 1980-2013 | 56 | 1 |
| Sales by Geographic Area, PhRMA Member Companies: 2012 | 57 | 1 |
| Domestic U.S. Biopharmaceutical R&D &R&D Abroad, PhRMA Member Companies: 1980-2013 | 58 | 1 |
| Domestic U.S. Biopharmaceutical R&D &R&D Abroad Breakdown, PhRMA Member Companies: 2012 | 59 | 2 |
